AI Article Synopsis
- Streptococcus suis is a zoonotic pathogen posing risks to public health, and Aditoprim (ADP) is a new veterinary medicine showing promise as an antibacterial treatment.
- The study developed a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model to determine optimal dosages and withdrawal intervals for ADP, predicting its effectiveness in different body tissues and the potential for bacterial resistance.
- Results indicate that administering ADP at 20 mg/kg over 3 days prevents resistance while ensuring food safety with an 18-day withdrawal interval before livestock can be processed for food.
Article Abstract
Streptococcus suis () is a zoonotic pathogen threatening public health. Aditoprim (ADP), a novel veterinary medicine, exhibits an antibacterial effect against . In this study, a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model was used to determine the dosage regimens of ADP against and withdrawal intervals. The PBPK model of ADP injection can predict drug concentrations in plasma, liver, kidney, muscle, and fat. A semi-mechanistic pharmacodynamic (PD) model, including susceptible subpopulation and resistant subpopulation, is successfully developed by a nonlinear mixed-effect model to evaluate antibacterial effects. An integrated PBPK/PD model is conducted to predict the time-course of bacterial count change and resistance development under different ADP dosages. ADP injection, administrated at 20 mg/kg with 12 intervals for 3 consecutive days, can exert an excellent antibacterial effect while avoiding resistance emergence. The withdrawal interval at the recommended dosage regimen is determined as 18 days to ensure food safety. This study suggests that the PBPK/PD model can be applied as an effective tool for the antibacterial effect and safety evaluation of novel veterinary drugs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11061430 | PMC |
| http://dx.doi.org/10.3389/fphar.2024.1378034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What matters for drug delivery to tumor by nanoparticles: Gaining insights from PBPK/PD simulation of drug nanocrystals.
ADMET DMPK
July 2024
Department of Industrial & Physical Pharmacy, Purdue University, West Lafayette, Indiana, United States.
Background And Purpose: In our previous studies, drug nanocrystals were directly prepared by solution crystallization, possessing uniform particle size and morphology suitable for intravenous (IV) injection. These nanocrystals accumulated in a small percentage of their injected dose in tumor-bearing mice but showed similar anti-tumor effectiveness and much-reduced side effects compared with current commercial solubilized and encapsulated delivery systems.
Experimental Approach: In this study, we aimed to delineate possible controlling factors for the pharmacokinetics (PK) and biodistribution behaviors of paclitaxel (PTX) nanocrystals tested in mice by applying physiologically based pharmacokinetics (PBPK) modeling, coupled with pharmacodynamics (PD) simulation, to the data.
Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients.
Sci Rep
August 2024
Department of Pharmacy, The Third People's Hospital of Chengdu, College of Medicine, Southwest Jiaotong University, Chengdu, China.
This study aimed to develop a physiologically based pharmacokinetic/pharmacodynamic model (PBPK/PD) of meropenem for critically ill patients. A PBPK model of meropenem in healthy adults was established using PK-Sim software and subsequently extrapolated to critically ill patients based on anatomic and physiological parameters. The mean fold error (MFE) and geometric mean fold error (GMFE) methods were used to compare the differences between predicted and observed values of pharmacokinetic parameters C, AUC, and CL to evaluate the accuracy of the PBPK model.
View Article and Find Full Text PDFProgress in physiologically based pharmacokinetic-pharmacodynamic models of amino acids in humans.
Curr Opin Clin Nutr Metab Care
November 2024
Department of Biomedical Physiology and Kinesiology.
Article Synopsis
- - The review discusses the importance of amino acids for health, their roles in proteins, metabolism, and signaling, and highlights the use of physiologically based pharmacokinetic and pharmacodynamic (PBPK-PD) modeling to better understand amino acid functions.
- - Recent PBPK-PD models have provided insights into amino acid metabolism, including how leucine affects muscle protein metabolism and optimal supplementation strategies for conditions like sickle-cell disease and seizure disorders.
- - These models offer potential for future research in various areas, such as treatments for sarcopenia, comparisons between animal and plant-based nutrition, and understanding nutrient-drug interactions in diseases like Parkinson’s.
Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms.
J Clin Pharmacol
November 2024
Bayer HealthCare SAS, Loos, France, on behalf of: Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer, AG, Germany.
As detailed information on the pharmacokinetics (PK) of labetalol in pregnant people are lacking, the aims of this study were: (1) to build a physiologically based PK (PBPK) model of labetalol in non-pregnant individuals that incorporates different CYP2C19 genotypes (specifically, *1/*1, *1/*2 or *3, *2/*2, and *17/*17); (2) to translate this model to the second and third trimester of pregnancy; and (3) to combine the model with a previously published direct pharmacodynamic (PD) model to predict the blood pressure lowering effect of labetalol in the third trimester. Clinical data for model evaluation was obtained from the scientific literature. In non-pregnant populations, the mean ratios of simulated versus observed peak concentration (C), time to reach C (T), and exposure (area under the plasma concentration-time curve, AUC) were 0.
View Article and Find Full Text PDFImpact of obesity and roux-en-Y gastric bypass on the pharmacokinetics of (R)- and (S)-omeprazole and intragastric pH.
CPT Pharmacometrics Syst Pharmacol
September 2024
Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
This study employed physiologically-based pharmacokinetic-pharmacodynamics (PBPK/PD) modeling to predict the effect of obesity and gastric bypass surgery on the pharmacokinetics and intragastric pH following omeprazole treatment. The simulated plasma concentrations closely matched the observed data from non-obese, morbidly obese, and post-gastric bypass populations. Obesity significantly reduces CYP3A4 and CYP2C19 activities, as reflected by the metabolic ratio [omeprazole sulphone]/[omeprazole] and [5-hydroxy-omeprazole]/[omeprazole].
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!